Ruxolitinib + Methylprednisolone
Phase 2RecruitingInterest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Graft-versus-host Disease
Conditions
Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Trial Timeline
May 14, 2025 → Apr 14, 2028
NCT ID
NCT06936566About Ruxolitinib + Methylprednisolone
Ruxolitinib + Methylprednisolone is a phase 2 stage product being developed by Incyte for Acute Graft-versus-host Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06936566. Target conditions include Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects.
What happened to similar drugs?
20 of 20 similar drugs in Acute Graft-versus-host Disease were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06936566 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Graft-versus-host Disease